NANO MRNA Co.,Ltd. (FRA:3NQ)
Germany · Delayed Price · Currency is EUR 0.8350
+0.0400 (5.03%)
Last updated: Nov 28, 2025, 9:03 AM CET
NANO MRNA Company Description
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan.
The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer.
Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material.
The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023.
NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Minato, Japan.
NANO MRNA Co.,Ltd.
| Country | Japan |
| Founded | 1996 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 20 |
| CEO | Shiro Akinaga |
Contact Details
Address: Atago Green Hills MORI Tower Minato Japan | |
| Phone | 81 3 6432 4791 |
| Website | nanomrna.co.jp |
Stock Details
| Ticker Symbol | 3NQ |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shiro Akinaga | Chief Executive Officer |
| Koji Fujimoto | Chief Financial Officer |